Pharmabiz1d
Merck’s pembrolizumab with berahyaluronidase alfa demonstrates noninferior PK compared to IV Keytruda in pivotal 3475A-D77 trial
Merck’s pembrolizumab with berahyaluronidase alfa demonstrates noninferior PK compared to IV Keytruda in pivotal 3475A-D77 trial: Rahway, New Jersey Saturday, March 29, 2025, 10 ...
FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda
The filing is based on late-stage data, which shows that treatment with the subcutaneous version of MRK's Keytruda is at ...
Mural Oncology: Phase 3 Clinical Trial Setback Undermines Company's Future Prospects
Mural Oncology's stock plummeted 57% after halting the Phase 3 ARTISTRY-7 trial for nemvaleukin alfa. Click here to read an ...
Precision Medicine Online1d
Krazati, Keytruda Score Median Progression-Free Survival of 27 Months in First-Line NSCLC
BMS is already testing the combo against just Keytruda as a first-line treatment in a Phase III trial in KRAS G12C-mutant and ...
Contract Pharma1d
Merck Seeks FDA Approval for Subcutaneous Pembrolizumab
Merck has shared data from the pivotal Phase 3 trial evaluating the subcutaneous administration of pembrolizumab together ...
BioSpace1d
BioNTech’s Bispecific Elicits Treatment Response in Majority of SCLC Patients
BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.
BioSpace1d
Merck’s Injectable Keytruda Matches IV Formula in Pivotal Trial
Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s ...
Pharmabiz1d
Immutep doses first patient in its TACTI-004 phase III clinical trial in first line non-small cell lung cancer
Sydney, Australia Friday, March 28, 2025, 18:00 Hrs [IST] ...
Clinical Trials Arena1d
MSD’s subcutaneous Keytruda non-inferior to IV version of blockbuster drug
Compared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda can cut the time spent in ...
Fierce Biotech1d
BioNTech shows off lung cancer survival data behind phase 3 push for red-hot bispecific
BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...
Summit Therapeutics: Major Upcoming Ivonescimab Data Catalyst May Not Be All It Seems (Rating Downgrade)
Summit Therapeutics' ivonescimab outperforms Keytruda in Phase 3 lung cancer trials. Crucial Western market approval depends ...
The Pharma Letter1d
Data boost ahead of FDA verdict on injectable Keytruda
US pharma major Merck & Co (NYSE: MRK) has shared the first results from a late-stage trial of a subcutaneous version of its ...